Medivir Gains on Combination Hepatitis Study: Stockholm Mover

Sept. 20 (Bloomberg) -- Medivir AB, a Swedish medical research company, rose the most in over two weeks in Stockholm trading after the company said it will perform a mid-stage combination study with its hepatitis C treatment simeprevir.

The shares rose as much as 4.7 percent, the biggest jump since Sept. 3. Medivir had increased 4 percent to 72 kronor as of 12:07 p.m. local time.

The aim of the phase IIa study is to see how many patients, suffering from chronic hepatitis C infection of genotype 1a or 1b, will be virus free 12 weeks after treatment, Stockholm-based Medivir said today in a statement. Simeprevir, which is developed jointly with Johnson & Johnson’s Janssen Research & Development Ireland, will be combined with Janssen’s non-nucleoside inhibitor TMC647055.

“This study is in line with Medivir’s and Janssen’s strategy to evaluate different combination possibilities with simeprevir for interferon-free HCV treatments,” Medivir’s head of Research and Development Charlotte Edenius said in the statement. “This will broaden our understanding of simeprevir.”

Simeprevir, or TMC435, is currently undergoing a late stage study for treatment of chronic hepatitis C, Medivir said.

To contact the reporter on this story: Janina Pfalzer in Stockholm at jpfalzer@bloomberg.net.

To contact the editor responsible for this story: Christian Wienberg at cwienberg@bloomberg.net.